A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy

Essential Hypertension Clinical Trial

Official title:

A Randomized, Double-blind, Multi-center, Phase III Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil Combination in Patients With Essential Hypertension Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02368652
• Other study ID #: CJ_CCA_301A
• Status: Completed
• Phase: Phase 3
• Start date: December 2014
• Est. completion date: November 2015

Study information

• Verified date: May 2023
• Source: HK inno.N Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Compare the safety and efficacy of amlodipine besylate and candesartan cilexetil combination therapy on patients of essential hypertension who are not properly controlled by candesartan cilexetil monotherapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 181
• Est. completion date: November 2015
• Est. primary completion date: November 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years to 75 Years

Eligibility

Inclusion Criteria:

• Male or female aged = 19 and = 75 years old

• Subject with essential hypertension

• Subject who have voluntarily agreed to participate in the trial and signed the written informed consent form, after having listened to the purpose, method, and effect of the clinical trial

Exclusion Criteria:

• Subject who is siDBP = 120 mmHg or siSBP = 200 mmHg at Visit 1 (screening)

• Subject with difference in the mean blood pressure of over 10 mmHg for siDBP or 20 mmHg for siSBP between both arms at the screening visit

• Subject with known or suspected secondary hypertension [Including but not limited to any of the following: renovascular diseases, adrenal medullary and cortical hyperfunctions, coarctation of the aorta, primary hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's syndrome, pheochromo-cytoma, polycystic kidney disease, etc.]

• Subject with symptomatic orthostatic hypotension(a sudden fall in siDBP of at least 10 mmHg or siSBP of at least 20 mmHg after standing compared with blood pressure from the sitting or supin position)

• Subject with type 1 or type 2 diabetes mellitus with poor glucose control (defined as subject on inculin treatment, with HbA1c > 9.0% or with a modification in the oral anti-hyperglycemic medication regiment within the past 12 weeks prior to visit 1)

• Subject with severe heart disease(congestive heart failure(NYHA class 3 or 4), ischemic heart disease within the past 6 months(unstable angina, myocardial infarction), peripheral blood vascula disease, history of Percutaneous Transluminal Coronary Angioplasty or coronary artery bypass grafting)

• Subject with clinically significant ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically significant arrhythmia

• Subject with hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, haemodynamically relevant stenosis of the aortic or mitral valve

• Subject with cardiogenic shock

• Subject with severe cerebrovascular disease (history of stroke, cerebral infraction, or cerebral hemorrhage within the past 6 months)

• Subject with a history of or ongoing wasting disease, autoimmune diseases(rheumatoid arthritis, systemic lupus erythematosus, etc.) or connective tissue disease

• Subject with known moderate or malignant retinopathy (history of retinal signs of hemorrhage, visual impairment, retinal microaneurysm etc. within the past 6 months)

• Subject with any surgical or medical condition of the gastrointestinal tract that might sugnificantly alter the absorption, distribution, metabolism or excretion of the drug

• Subject with a history of malignant tumors including leukemia and lymphoma within the past 5 yesrs(except for localized basal cell carcinoma of the skin)

• Subject with any chronic inflammatory condition needing chronic anti-inflammatory therapy

• Subject with chronic kidney disase on dialysis

• Subject with the following clinically significant laboratory abnormalities:

• AST or ALT > 3 x Upper Limit Normal(ULN)

• Serum Creatinine > 1.5 ULN

• Serum potassium < 3.5 mmol/L or > 5.5mmol/L

• Subject requiring concomitant use of other antihypertensive or contraindicated drugs during the entire study period

• Subject with known or suspected contraindications, including history of allergy or hypersensitivity to ARB or dihydropyridine derivatives

• Subject who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or ARB

• Pregnant women or lactating mother, women suspected of being pregnant, women who wish to be pregnant during the study or women of child-bearing potential who are not using medically acceptable methods of contraception (oral contraceptinve, intra-uterine device, condom, etc.), except for women with surgical sterilization. Pre-menopausal women who are not surgically sterilized must have a negative pregnancy test result at Visit1 and maintain acceptable methods of contraception throughout the study. preiodic abstinence (eg. symptothermal, calendar, post-ovulation methods), or hormonal contraceptive are not acceptable methods of contraception

• History of drug or alcohol abuse within the past 1 year

• Use of other investigational products within the past 4 weeks

• Subject who are jdged unsuitable to participate in the study in the opinion of the investigator

Related Conditions & MeSH terms

• Essential Hypertension
• Hypertension

Intervention

Drug:
• Candesartan cilexetil 16mg
Daily oral administration for 8 weeks
• Amlodipine 10mg, Candesartan cilexetil 16mg
Daily oral administration for 8 weeks

Locations

Country	Name	City	State
Korea, Republic of	Hallym University Sungsim Hospital	Anyang-si
Korea, Republic of	Inje University Busan Baik Hospital	Busan
Korea, Republic of	Inje University Haeundae Baik Hospital	Busan
Korea, Republic of	Yeungnam University Medical Center	Daegu
Korea, Republic of	Chonnam National University Hospital	Gwangju
Korea, Republic of	Inje University Ilsan Baik Hospital	Ilsan
Korea, Republic of	Inha University Hospital	Incheon
Korea, Republic of	Seoul National University Bundang Hospital	Seongnam-si
Korea, Republic of	Asan Medical Center	Seoul
Korea, Republic of	Ewha Womans University Mokdong Hospital	Seoul
Korea, Republic of	Gangbuk Samsung Hospital	Seoul
Korea, Republic of	Korea University Anam Hospital	Seoul
Korea, Republic of	Korea University Guro Hospital	Seoul
Korea, Republic of	Seoul Medical Center	Seoul
Korea, Republic of	Seoul St. Mary's Hospital Catholic University	Seoul
Korea, Republic of	Soonchunhyang University Hospital	Seoul
Korea, Republic of	Yonsei University Severance Hospital	Seoul
Korea, Republic of	Ajou University Hospital	Suwon
Korea, Republic of	Wonju Severance Christian Hospital	Wonju

Sponsors (1)

Lead Sponsor	Collaborator
HK inno.N Corporation

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in sitting Diastolic Blood Pressure (siDBP) at week 8 compared to baseline		Week 8
Secondary	Change in siDBP at week 4		Week 4
Secondary	Change in sitting Systolic Blood Pressure (siSBP) at week 4 and 8		Week 4 and 8
Secondary	Proportion of patients achieving ?siDBP = 10 mmHg and ?siSBP = 20 mmHg after 8 weeks		Week 8
Secondary	Proportion of patients achieving siDBP < 90 mmHg and siSBP < 140 mmHg after 8 weeks		Week 8